News & Updates
Filter by Specialty:
STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).
STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
02 Sep 2024
Empagliflozin reduces hepatic fat content in nondiabetic MASLD patients
Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.
Empagliflozin reduces hepatic fat content in nondiabetic MASLD patients
02 Sep 2024
Tau-PET: Best predictor for dementia progression in MCI patients
Tau-PET outperforms amyloid-β (Aß) PET and MRI as the best neuroimaging marker for predicting progression to dementia in patients with mild cognitive impairment (MCI), a cohort study has shown.
Tau-PET: Best predictor for dementia progression in MCI patients
02 Sep 2024
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.
